載入...
Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report
Gefitinib, the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non-small cell lung cancer (NSCLC) with common EGFR mutation. However, the efficacy of preoperative gefitinib therapy in p...
Na minha lista:
| 發表在: | J Thorac Dis |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212137/ https://ncbi.nlm.nih.gov/pubmed/32395295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.02.60 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|